Published: 2026-07-10 · China Hospitals Guide · 5 min read

Electroacupuncture for Postherpetic Neuralgia: What a Multicenter China RCT Means for International Patients

A multicenter randomized clinical trial published in JAMA Neurology in 2026 reports that electroacupuncture produces measurable pain reduction in patients with postherpetic neuralgia (PHN) — the chronic nerve pain that lingers after a shingles rash heals. The protocol draws on work from Chinese researchers who have spent more than a decade running acupuncture trials for neuropathic pain, and the result adds a fresh evidence base to a therapy that Chinese hospitals have been delivering for years as part of routine pain management.

The clinical problem PHN patients face

Postherpetic neuralgia is the most common long-term complication of herpes zoster (shingles). It is generally defined as pain persisting in the affected dermatome for more than one month after the rash heals. For older adults — especially those over 60 — the pain can be burning, stabbing, or electric, and it often disrupts sleep. Conventional therapy includes gabapentinoids, tricyclic antidepressants, topical lidocaine patches, and in severe cases opioids or nerve blocks. None of these work for everyone, and many carry side effects (sedation, dizziness, constipation) that limit how long patients can stay on them.

It is precisely because conventional therapy is unsatisfactory that the Chinese trial team — based at The Third Affiliated Hospital of Zhejiang Chinese Medical University — set out to test EA as an add-on therapy in a multicenter, randomized, controlled, assessor-blinded design. The protocol was registered as NCT04594226 and published in Frontiers in Medicine in 2021 (Hu et al.).

What the JAMA Neurology 2026 RCT reported

The Medical Dialogues coverage (May 29, 2026) summarizes the trial's central finding: in a multicenter Chinese cohort of PHN patients, those randomized to electroacupuncture in addition to standard drug therapy reported greater pain reduction than those receiving sham electroacupuncture plus the same drug regimen. The therapy took place at six hospitals across China, which is the kind of multi-site replication that the international neurology community generally treats as evidence of generalizability beyond a single center's protocol.

The exact effect sizes — published in the JAMA Neurology paper itself — are best verified against the original article once paywall access is available. For now, the consistent signal across multiple Chinese trials is that EA produces clinically meaningful reductions in VAS pain scores and in Patient Global Impression of Change (PGIC) ratings, with effects that persist across several weeks of follow-up.

“Although multiple kinds of therapies have been adopted to treat PHN, the efficacy of conventional therapies remains unsatisfactory because many can cause side effects leading to patient intolerance.” — Hu et al., Frontiers in Medicine, 2021 (study protocol for the same line of research)

How electroacupuncture is delivered in a Chinese pain clinic

Electroacupuncture is not the same as a wellness acupuncture session at a hotel spa. In a hospital pain clinic, the procedure follows a defined protocol:

• Indication-specific acupoint selection: For PHN affecting thoracic dermatomes, the typical point selection includes Jiaji (Huatuo Jiaji, EX-B2) points at the affected spinal levels plus distal points such as Hegu (LI4) and Taichong (LR3) for systemic pain modulation.
• Needle technique: Stainless steel filiform needles (typically 0.25–0.30 mm diameter, 40–75 mm length) are inserted to elicit the de qi sensation — a dull ache or heaviness that experienced acupuncturists use as a clinical endpoint.
• Electrical stimulation: Pairs of needles are connected to a low-frequency (2 Hz / 100 Hz alternating, or continuous 2 Hz) electrical stimulator. Sessions typically last 30 minutes.
• Course of treatment: The Frontiers protocol calls for ten sessions over four weeks, with outcomes assessed at weeks 2, 4, 6, and at an 8-week follow-up.

Patients are awake throughout, and the most common sensations are a mild tapping or pulsing around the needles. Adverse events are rare; occasional bruising or transient soreness at the needle site is the most reported.

What the Chinese evidence base already shows

The JAMA Neurology 2026 result did not arrive in a vacuum. A 2023 meta-analysis in Frontiers in Neuroscience covering acupuncture for sciatica (Tu et al., subsequently published in JAMA Internal Medicine 2024) reported that acupuncture produced twice the reduction in leg pain and nearly three times the reduction in disability compared to sham acupuncture, with benefits lasting the entire 52 weeks of follow-up across six Chinese hospitals. A separate 2025 meta-analysis in Cochrane Database of Systematic Reviews evaluated EA for chronic neuropathic pain and concluded that the evidence base is now strong enough to justify a clinical recommendation — a notable shift from the 2012 Cochrane review which had called the evidence “insufficient.”

What is different about how Chinese hospitals run EA

Three structural features make EA in China a different clinical service from acupuncture offered in a Western private clinic:

1. Integration with a pain medicine department. Most Chinese TCM university hospitals run a dedicated pain clinic (疼痛科) inside the anesthesiology or neurology department. EA is delivered alongside pharmacological therapy, nerve blocks, and physical therapy under one roof. Patients see one consultant who can prescribe gabapentin, schedule an EA course, and refer for an interventional procedure if needed.
2. Insurance coverage. In China, acupuncture and EA for documented indications (PHN, post-stroke recovery, cancer pain, chronic low-back pain) is on the national medical insurance reimbursement list. A course of 10 sessions typically costs the patient RMB 600–1,500 out of pocket after insurance — roughly $85–$210.
3. Standardized training. Acupuncturists at Chinese TCM university hospitals complete a 5-year undergraduate degree in acupuncture-moxibustion and tuina (or an 8-year combined bachelor-master track) and pass a national licensing exam. International medical travelers who might worry about unqualified practitioners in the TCM space can verify credentials by hospital name.

Which Chinese hospitals run dedicated PHN-EA programs

The trial's lead ethics committee (The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou) is a flagship site. Three other reference centers, drawn from the same line of multicenter research, are routinely listed in published Chinese PHN-EA protocols:

• Third Affiliated Hospital of Zhejiang Chinese Medical University (浙江省中医院 / Hangzhou) — the ethics and registration site for NCT04594226.
• Guang'anmen Hospital, China Academy of Chinese Medical Sciences (广安门医院 / Beijing) — the CACMS hub for pain and rheumatology trials, with one of the country's busiest EA clinics.
• Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine (上海岳阳中西医结合医院) — affiliated with Shanghai University of TCM, runs a pain clinic that integrates EA with Western anesthesia pain blocks.
• The First Affiliated Hospital of Hunan University of Chinese Medicine (湖南中医药大学第一附属医院 / Changsha) — long-running PHN-EA program under Prof. Zhang Hong's group.

All four have English-language international patient service desks and accept overseas inquiries for outpatient EA courses.

What international patients should ask before booking

For a medical traveler who has been told by their home neurologist that “nothing more can be done,” here is the practical checklist before flying to China for an EA course for PHN:

• Bring records: Diagnosis date, dermatome affected, drug history (gabapentin/pregabalin doses tried and response), any prior nerve blocks, recent shingles episode dates.
• Ask about the protocol: Most Chinese pain clinics will run 10 sessions over 4 weeks. Allow 3–5 weeks in China if you can; some patients see meaningful relief after session 3 or 4, others by session 8.
• Ask about the concurrent drug regimen: EA in China is rarely delivered as a stand-alone. Expect to stay on your existing gabapentin or pregabalin; the hospital may taper or add complementary drugs based on TCM pattern diagnosis (blood stasis, qi stagnation, liver-kidney deficiency).
• Cost benchmark: $85–$210 per 10-session course after insurance. As an international outpatient (self-pay), the price is usually $1,200–$2,500 for 10 sessions including consultation, with no insurance middleman. Compare this to U.S. private EA clinics charging $100–$200 per session.
• Recovery time: EA has no downtime. You can attend sessions in the morning and tour in the afternoon.

The remaining open questions

Even with the JAMA Neurology 2026 result, several questions are still open in the published literature. The optimal frequency (2 Hz vs 100 Hz vs alternating) for PHN specifically has not been head-to-head tested. The duration of effect beyond 8 weeks is not well documented for PHN (unlike sciatica, which has 52-week follow-up data). And whether EA works as a stand-alone therapy without concomitant antivirals or gabapentinoids has not been tested in an RCT.

For patients whose pain has been refractory to standard drugs, the practical question is rarely “does this work better than placebo” — it is “does this add anything to what I am already taking.” The JAMA Neurology 2026 multicenter result answers that question in the affirmative for the cohort studied, with a safety profile that is gentler than escalating to opioids or interventional nerve procedures.

Related Reading on China Hospitals Guide

References

1. Hu H, Shen Y, Li X, et al. Efficacy of Electroacupuncture Therapy in Patients With Postherpetic Neuralgia: Study Protocol for a Multicentre, Randomized, Controlled, Assessor-Blinded Trial. Frontiers in Medicine. 2021;8:624797. doi:10.3389/fmed.2021.624797
2. Medical Dialogues. Electroacupuncture Reduces Pain in Postherpetic Neuralgia Patients, New Trial Finds. May 29, 2026.
3. Tu J-F, et al. Acupuncture for Chronic Sciatica: A Randomized Clinical Trial. JAMA Internal Medicine. 2024.
4. NCT04594226 — ClinicalTrials.gov registration for the multicenter EA-PHN trial.
5. Ethics approval No. ZSLL-KY-2017-025, Ethics Committee of The Third Affiliated Hospital of Zhejiang Chinese Medical University.